Sell Ranbaxy Laboratories: Sriram Rathi

Sriram Rathi, pharma analyst at Anand Rathi told CNBC-TV18, "We have a sell rating on Ranbaxy Laboratories with a target of Rs 375. From a fundamental perspective we don't see any major trigger for this stock for over next one and half years or so and the margins will continue to remain under pressure."

At 12:20 hrs Ranbaxy Laboratories was quoting at Rs 457.10, up Rs 6.35, or 1.41 percent. It has touched an intraday high of Rs 459.35 and an intraday low of Rs 451.75.

The share touched its 52-week high Rs 525 and 52-week low Rs 253.95 on 03 January, 2013 and 02 August, 2013, respectively. Currently, it is trading 12.93 percent below its 52-week high and 80 percent above its 52-week low. Market capitalisation stands at Rs 19,369.24 crore.